中国药业2016，Vol.25Issue(11)：25-27,35,4.
阿托伐他汀联合氨氯地平早期大剂量用于高血压并急性冠脉综合征的临床评价
Early Application of Large Dose of Atorvastatin Combined with Amlodipine on Hypertension and Acute Coronary Syndrome
向阳 1李萍 1鄢学1
作者信息
- 1. 重庆市万州区人民医院，重庆 404100
- 折叠
摘要
Abstract
Objective To investigate the efficacy and safety of high dose atorvastatin combined with levamlodipine besylate on hyperten-sion and acute coronary syndrome within 12 h. Methods 90 hospitalized patients with hypertension and acute coronary syndrome from January 2013 to January 2015were selected. The regular treatment of all patients was according to the guidelines. The end time was 12 months and the patients were followed up at 4th month and 12th month. The experimental group of 45 cases was given atorvastatin 80 mg and levamlodipine besylate 10 mg at a draught within 12 hours, then took atorvastatin 40 mg and levamlodipine besylate 5 mg once every night as usual. The control group of 45 cases was given atorvastatin 10 mg and levamlodipine besylate 10 mg at a draught within 12 hours, then took atorvastatin 10 mg and levamlodipine besylate 5 mg once every night as usual. The blood lipid, blood pressure, cardiovascu-lar events and adverse reactions were followed up in the two groups. Results The study showed that after treatment the blood pressure and blood lipid were significantly decreased in the two group( P ﹤ 0. 05), but the experimental group decreased more obviously( P ﹤ 0. 05). There were no significantly differences in adverse reactions between two groups( P ﹥ 0. 05); no serious cardiovascular events occurred in the two groups. Conclusion The application of high dose atorvastatin plus levamlodipine besylate within 12 hours can improve clinical prognosis of patients with hypertension and acute coronary syndrome, obtain more benefit without serious adverse events.关键词
阿托伐他汀钙/苯磺酸左旋氨氯地平/高血压/急性冠脉综合征Key words
atorvastatin/levamlodipine besylate/hypertension/acute coronary syndrome分类
医药卫生引用本文复制引用
向阳,李萍,鄢学..阿托伐他汀联合氨氯地平早期大剂量用于高血压并急性冠脉综合征的临床评价[J].中国药业,2016,25(11):25-27,35,4.
